CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.

Geeta KaradkheleJulien HoganWairimu MaguaWeiwen ZhangIdelberto Raul BadellAneesh MehtaMarshall LyonStephen O PastanThomas C PearsonChristian P Larsen

Published in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)

Belatacept-based maintenance immunosuppression is associated with an increased risk of CMV primary-infection and a prolonged course of viral replication in CMV high-risk patients. Further studies are needed to confirm the nonsignificant trend towards a lower graft survival in CMV high-risk patients treated with belatacept and whether it is explained by the higher risk of CMV reactivation and infection.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
sars cov
prognostic factors
type diabetes
adipose tissue
skeletal muscle
insulin resistance
case control